Equities analysts expect that Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) will report earnings of ($0.14) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Achillion Pharmaceuticals’ earnings. Achillion Pharmaceuticals posted earnings of ($0.12) per share during the same quarter last year, which would suggest a negative year over year growth rate of 16.7%. The business is scheduled to report its next earnings results on Wednesday, August 14th.
On average, analysts expect that Achillion Pharmaceuticals will report full year earnings of ($0.59) per share for the current year. For the next fiscal year, analysts anticipate that the firm will report earnings of ($0.67) per share. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that follow Achillion Pharmaceuticals.
Achillion Pharmaceuticals (NASDAQ:ACHN) last posted its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, hitting the consensus estimate of ($0.14).
Several research firms have recently weighed in on ACHN. BidaskClub upgraded Achillion Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, March 14th. Barclays downgraded Achillion Pharmaceuticals from an “equal weight” rating to an “underweight” rating and cut their price target for the stock from $5.00 to $2.50 in a research note on Friday, May 3rd. Zacks Investment Research downgraded Achillion Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, May 20th. Finally, William Blair reiterated an “outperform” rating on shares of Achillion Pharmaceuticals in a research note on Thursday, March 7th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the company’s stock. Achillion Pharmaceuticals has an average rating of “Hold” and a consensus target price of $2.50.
Shares of ACHN stock traded up $0.08 on Monday, hitting $2.86. 724,161 shares of the stock were exchanged, compared to its average volume of 1,702,364. The company has a market capitalization of $385.67 million, a price-to-earnings ratio of -5.61 and a beta of 2.34. Achillion Pharmaceuticals has a one year low of $1.29 and a one year high of $3.98.
Institutional investors and hedge funds have recently modified their holdings of the stock. Virtu Financial LLC purchased a new stake in Achillion Pharmaceuticals during the 1st quarter worth about $33,000. Acadian Asset Management LLC purchased a new stake in Achillion Pharmaceuticals during the 4th quarter worth about $41,000. Meeder Asset Management Inc. lifted its holdings in Achillion Pharmaceuticals by 107.3% during the 4th quarter. Meeder Asset Management Inc. now owns 26,476 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 13,706 shares in the last quarter. Norges Bank purchased a new stake in Achillion Pharmaceuticals during the 4th quarter worth about $55,000. Finally, Parametric Portfolio Associates LLC lifted its holdings in Achillion Pharmaceuticals by 21.4% during the 1st quarter. Parametric Portfolio Associates LLC now owns 21,014 shares of the biopharmaceutical company’s stock worth $62,000 after purchasing an additional 3,700 shares in the last quarter. 79.30% of the stock is currently owned by institutional investors and hedge funds.
About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.